Trump Administration Seeks to Dismiss Lawsuit Against Mifepristone Access
The Trump administration aims to dismiss a lawsuit from GOP states challenging telehealth access to mifepristone, citing lack of legal standing.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get StartedHave an account? Sign in
Overview
The Trump administration is asking a Texas federal judge to dismiss a lawsuit from Missouri, Idaho, and Kansas that seeks to limit access to mifepristone, a medication abortion drug. The Justice Department argues the states lack legal standing and connection to Texas, asserting that the states can pursue their claims elsewhere. This follows previous Supreme Court rulings these states failed to establish harm related to the FDA's regulations expanding mifepristone access. The legal battle highlights ongoing tensions regarding abortion access and state versus federal authority.
Report issue
Read both sides in 5 minutes each day
Analysis
Analysis unavailable for this viewpoint.
Articles (4)
FAQ
The Trump administration maintained the defense of mifepristone primarily on procedural grounds, such as questioning the legal standing and venue of the challenging states, rather than explicitly supporting the Biden administration's policy on the drug.
The states are challenging the FDA's actions that allowed the use of mifepristone up to ten weeks of pregnancy and the mail delivery of the drug without an in-person clinician visit.
The Comstock Act, a 19th-century anti-obscenity law, was mentioned by plaintiffs arguing that mailing mifepristone violates this law.
History
- This story does not have any previous versions.